In addition, availability of pirtobrutinib could also help fill an existing major area of unmet need in CLL—an effective therapy for post-covalent BTKi and post-venetoclax treated patients.44 Real-world data cited previously already suggests that in ‘double-exposed’ patients, treatment with a non-covalent BTK inhibitor leads to longer PFS than PI3 K inhibitors or chemoimmunotherapy.43 The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.